US Generic Drug Spending Declines In A New Development – IQVIA Report

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.